Clinical trials and research for prostate cancer
We lead research to improve the lives of prostate cancer patients – now and in the future. Have a question about trials or research at the E.J. Whitten Prostate Cancer Research Centre at Epworth? Contact us:
Phone: 03 9483 6035
Email: [email protected]
Research and clinical trials lead to advances in medicine. They help researchers to find better treatments and ways to improve your overall patient experience. Sometimes, a clinical trial is the only way to access a new treatment option, years before it is available to the public.
At Epworth, innovation is in our DNA. We performed the first robot assisted radical prostatectomy in Australia and continue to excel in prostate cancer surgery. We are proud to offer our prostate cancer patients every chance to access the latest developments. You have support from us at every step, in person and through telehealth for regional and interstate patients.
Taking part in a clinical trial, study or registry is voluntary and always your choice.
-
What is a clinical trial for prostate cancer?
A clinical trial tests how safe and effective an intervention is. In medical terms, an intervention is something prescribed with the aim to improve health, such as a treatment or drug. It may also be a surgical method or exercise program.
Clinical trials also test existing treatments for different diseases or in different doses. They compare the new intervention with existing options.
-
What is a research study for prostate cancer?
A research study aims to answer important questions to improve prostate cancer care, including prevention, screening, diagnosis or patient experience. .
Research studies are observational, rather than interventional like clinical trials. This means you don’t receive a treatment. Instead, a research study may ask you questions about your experiences, feelings or treatment side effects.
-
How can I join a trial or study?
You can browse our active projects below or speak with the team to find out more. We welcome questions from you or your treating doctor on 03 9483 6035 or [email protected]
Active prostate cancer trials and research at Epworth
Listing updated: 15 June 2022
Prostate cancer stage |
Study title |
Basic criteria |
Principal Investigator/Contact |
|
Newly diagnosed metastatic prostate cancer M1a, M1b, M1c (TNM staging) |
SIMCAP |
Exclusion:
|
Prof Nathan Lawrentschuk |
|
Low grade prostate cancer |
CONFIRM The Diagnostic Utility of PSMA PET/CT in Men with Newly Diagnosed Low-Grade Prostate Cancer with High-Risk Features, on Active Surveillance, Awaiting Confirmatory Biopsy |
Inclusion:
|
Prof Nathan Lawrentschuk |
|
High risk prostate cancer |
PRIMORDIUM A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH |
PSMA PET scan required at screening Inclusion:
Exclusion
|
A/Prof Arun Azad |
|
DDR gene mutated Castration-sensitive prostate cancer |
TALAPRO-3 Phase 3, randomized doubleblind study of talazoparib with enzalutamide versus placebo with enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer |
Prior treatments (allowed, but not mandatory):
|
A/Prof Arun Azad |
| mHSPCa or mCRPCa |
IRONMAN International Registry for Men with Advanced Prostate Cancer |
Observational | A/Prof Ben Tran |